Coherus BioSciences has announced the divestiture of its Humira biosimilar, YUSIMRY (adalimumab-aqvh), to Hong Kong-based King-Friend Industrial in a $40 million upfront all-cash transaction. This move is part of Coherus' strategic realignment. Meanwhile, the Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on PTC Therapeutics' Translarna™ following a European Commission request for review. This opinion follows the return of a previously issued negative opinion by the European Commission for re-review. PTC plans to request a re-examination of the opinion. Additionally, Apellis Pharmaceuticals plans to seek re-examination following a negative CHMP opinion on the Marketing Authorization Application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) in the EU.
EU's drug regulator again rejects Apellis' eye med and PTC's Translarna in busy week of up-and-down decisions https://t.co/H3vD2hVsKo
News Roundup: PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar https://t.co/MXz7MhHZEN
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar https://t.co/uXwT3H45Ro $PTCT $CHRS $VIGL $ESPR
$APLS (-5.4% pre) Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU - SI https://t.co/82YLq2A5L2
$APLS CHMP has adopted a negative opinion on the MAA of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA).
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU $APLS https://t.co/7DQIVXA3NX
Coherus BioSciences announced it agreed to sell its Humira biosimilar Yusimry to Hong Kong-based King-Friend Industrial for $40M in cash. Which biosimilars are covered by the top 3 prescription drug insurance /PBM formularies? Hyrimoz is jointly marketed by CVS-owned Cordavis https://t.co/zaZyAQS3Ha
$PTCT CHMP Issues Negative Opinion on Translarna Following European Commission Request for Review. This opinion follows the return of the previously issued negative opinion by the EC for re-review. PTC plans to request a re-examination of the opinion.
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review $PTCT https://t.co/H8AxqxCeJN
Coherus divests 'biosimilar' of Humira for $40 million upfront $CHRS https://t.co/LNl58Fem96 via @SFBusinessTimes
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction $CHRS https://t.co/MGA62VFYKJ